Temporal trends in short and long-term outcomes after percutaneous coronary interventions among cancer patients.
Acute coronary syndrome
Cardio-oncology
Percutaneous intervention
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
18
12
2020
accepted:
19
02
2021
pubmed:
2
3
2021
medline:
9
2
2022
entrez:
1
3
2021
Statut:
ppublish
Résumé
While mortality of acute coronary syndrome (ACS) is known to have steadily decline over the last decades, data are lacking regarding the complex sub-population of patients with both coronary artery disease and cancer. A large single-center percutaneous coronary intervention (PCI) registry was used to retrieve patients who had a known diagnosis of malignancy during PCI. Patients were divided into two groups according to the period in which PCI was performed (period 1: 2006-2011, period 2: 2012-2017). Cox regression hazard models were implemented to compare primary endpoint, defined as the composite outcomes of major adverse cardiac events (MACE) (which include cardiovascular death, myocardial infarction or target vessel revascularization) and secondary endpoint of all-cause mortality, between the two time periods. A total of 3286 patients were included, 1819 (55%) had undergone PCI in period 1, and 1467 (45%) in period 2. Both short- and long-term MACE and overall mortality were significantly lower in patients who underwent PCI at the latter period (2.3% vs. 4.3%, p < 0.001 and 1.1% vs. 3.2%, p < 0.001 after 30 days and 24% vs. 30%, p < 0.001 and 12% vs. 22%, p < 0.001 after 2 years, respectively). However, in a multivariate analysis, going through PCI in the latter period was still associated with lower rates of overall mortality (HR 0.708, 95% confidence interval [CI] 0.53-0.93, p = 0.014) but there was no significant difference in MACE (HR 0.83, 95% CI 0.75-1.42, p = 0.16). Patients with cancer undergoing PCI during our most contemporary period had an improved overall survival, but no significant differences were observed in the composite cardiovascular endpoints, compared to an earlier PCI period. The management of coronary patients with cancer disease remains challenging.
Identifiants
pubmed: 33646432
doi: 10.1007/s00380-021-01817-y
pii: 10.1007/s00380-021-01817-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1283-1289Informations de copyright
© 2021. Springer Japan KK, part of Springer Nature.
Références
Zoller B, Ji J, Sundquist J, Sundquist K (2012) Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer 48:121–128
doi: 10.1016/j.ejca.2011.09.015
Agmon Nardi I, Iakobishvili Z (2018) Cardiovascular risk in cancer survivors. Curr Treat Options Cardiovasc Med 20:47
doi: 10.1007/s11936-018-0645-8
Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34
doi: 10.3322/caac.21551
Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C (2016) Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34(10):1122–1130
doi: 10.1200/JCO.2015.64.0409
Bharadwaj A, Potts J, Mohamed MO, Parwani P, Swamy P, Lopez-Mattei JC, Rashid M, Kwok CS, Fischman DL, Vassiliou VS, Freeman P, Michos ED, Mamas MA (2020) Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J 41(23):2183–2193
doi: 10.1093/eurheartj/ehz851
Hess CN, Roe MT, Clare RM, Chiswell K, Kelly J, Tcheng JE, Hagstorm E, James SK, Khouri MG, Hirsch BR, Kong DF, Abernethy AP, Krucoff MW (2015) Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention. J Am Heart Assoc 4:e001779
doi: 10.1161/JAHA.115.001779
Tabata N, Sueta D, Yamamoto E, Takashio S, Arima Y, Araki S, Yamanaga K, Ishii M, Sakamoto K, Kanazawa H, Fujisue K, Hanatani S, Soejima H, Hokimoto S, Izumiya Y, Kojima S, Yamabe H, Kaikita K, Tsujita K (2018) Outcomes of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. Eur Heart J Qual Care Clin Outcomes 4:290–300
doi: 10.1093/ehjqcco/qcx047
Iannaccone M, D’Ascenzo F, Vadala P, Wilton SB, Noussan P, Colombo F, Roubin SR, Abu Assi E, Gonzales-Juanatey JR, Henriques JPS, Saucedo J, Kikkert WJ, Nunez-Gil I, Ariza-Sole A, Song XT, Alexopoulos D, Liebetrau C, Kawaji T, Moretti C, Garbo R, Huczek Z, Nie SP, Fujii T, Correia LC, Kawashiri MA, Acuna JMG, Southern D, Alfonso E, Terol B, Garay A, Zhang D, Chen Y, Xanthopoulou I, Osman N, Mollmann H, Shiomo H, Giordana F, Kowara M, Filipiak K, Wang X, Yan T, Fan JY, Ikari Y, Nakahashi T, Sakata K, Gaita F, Yamagishi M, Kalpak O, Kedev S (2018) Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention; a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care 7:631–638
doi: 10.1177/2048872617706501
Al-Hawwas M, Tsitlakidou D, Gupta N, Iliescu C, Cilingiroglu M, Marmagkiolis K (2018) Acute coronary syndrome management in cancer patients. Curr Oncol Rep 20:78
doi: 10.1007/s11912-018-0724-8
Zamorano JL, Lancellotti P, Munoz DR, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Fernandez TL, Mohty D, Piepoli MF, Tamargo J, Torbicki STM (2016) ESC Scientific Document Group. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801
doi: 10.1093/eurheartj/ehw211
Iakobishvili Z, Kornowski R (2015) Can cardio-oncology deliver better care internationally? Future Oncol 11(16):2259–2262. https://doi.org/10.2217/fon.15.133
doi: 10.2217/fon.15.133
pubmed: 26260804
Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM (2017) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70:926–938
doi: 10.1016/j.jacc.2017.06.047
Yeh ETH, Chang HM (2017) Cancer and clot: between a rock and a hard place. J Am Coll Cardiol 70:939–941
doi: 10.1016/j.jacc.2017.07.719
Tabata N, Sueta D, Yamamoto E, Takashio S, Arima Y, Araki S, Yamanaga K, Ishii M, Sakamoto K, Kanazawa H, Fujisue K, Hanatani S, Soejime H, Hokimoto S, Izumiya Y, Kojima S, Yamabe H, Kaikita K, Matsui K, Tsujita K (2019) A retrospective study of arterial stiffness and subsequent clinical outcomes in cancer patients undergoing percutaneous coronary intervention. J Hypertens 37(4):754–764
doi: 10.1097/HJH.0000000000001949
Sueta D, Tabata N, Ikeda S, Saito Y, Ozaki K, Sakata K, Matsumura T, Yamamoto-Ibusuki M, Murakami Y, Jodai T, Fukushima S, Yoshida N, Kamba T, Araki E, Iwase H, Fujii K, Ihn H, Kobayashi Y, Minamino T, Yamagishi M, Maemura K, Baba H, Matsui K, Tsujita K (2019) Differential predictive factors for cardiovascular events in patients with or without cancer history. Medicine 98(44):e17602
doi: 10.1097/MD.0000000000017602
Grivennikov S, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899
doi: 10.1016/j.cell.2010.01.025
Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, Gibson CM, Braunwald E (2005) Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111:2042–2049
doi: 10.1161/01.CIR.0000162477.70955.5F
Quintana RA, Monlezun DJ, Davogustto G, Saenz HR, Lozano-Ruiz F, Sueta D, Tsujita K, Landes U, Denktas AE, Alam M, Paniagua D, Addison D, Jneid H (2020) Outcomes following percutaneous coronary intervention in patients with cancer. Int J Cardiol 300:106–112
doi: 10.1016/j.ijcard.2019.09.016
Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans A, Cannegieter SC, Jukema W, Umans V, Schalij MJ, van Boven AJ (2013) Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol 112:1867–1872
doi: 10.1016/j.amjcard.2013.08.019
Janssen-Heijnen ML, Szerencsi K, van de Schans SA, Maas HA, Widdershoven JW, Coebergh JW (2010) Cancer patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort of 10 years older without cardiovascular morbidity. Crit Rev Oncol Hematol 76:196–207
doi: 10.1016/j.critrevonc.2009.11.004
Ederhy S, Cohen A, Boccara F, Puymirat E, Aissaoui N, Elbaz M, Bonnefoy-Cudraz E, Druelles P, Andrieu S, Angoulvant D, Furber A, Ferrieres J, Schiele F, Cottin Y, Simon T, Danchin N (2019) In hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French registry on Acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort. Arch Cardiovasc Dis 112:657–669
doi: 10.1016/j.acvd.2019.06.012
Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN (2012) Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 35(7):443–450
doi: 10.1002/clc.22007
Landes U, Kownowski R, Bental T, Assali A, Vaknin-Assa H, Lev E, Iakobishvili Z (2017) Long-term outcomes after percutaneous coronary interventions in cancer survivors. Coron Artery Dis 28(1):5–10
doi: 10.1097/MCA.0000000000000429
Itzhaki Ben Zadok O, Hasdai D, Gottlieb S, Porter A, Beigel R, Shimony A, Cohen T, Shlomo N, Shohat T, Silverman B, Kornowski R, Iakobishvili Z (2019) Characteristics and outcomes of patients with cancer presenting with acute myocardial infarction. Coron Artery Dis 30(5):332–338
doi: 10.1097/MCA.0000000000000733